JP2008519815A5 - - Google Patents

Download PDF

Info

Publication number
JP2008519815A5
JP2008519815A5 JP2007540716A JP2007540716A JP2008519815A5 JP 2008519815 A5 JP2008519815 A5 JP 2008519815A5 JP 2007540716 A JP2007540716 A JP 2007540716A JP 2007540716 A JP2007540716 A JP 2007540716A JP 2008519815 A5 JP2008519815 A5 JP 2008519815A5
Authority
JP
Japan
Prior art keywords
alkyl
hydrogen
use according
alkenyl
het
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007540716A
Other languages
English (en)
Japanese (ja)
Other versions
JP5274838B2 (ja
JP2008519815A (ja
Filing date
Publication date
Priority claimed from GB0425039A external-priority patent/GB0425039D0/en
Priority claimed from GB0510348A external-priority patent/GB0510348D0/en
Application filed filed Critical
Priority claimed from PCT/GB2005/004361 external-priority patent/WO2006051314A2/en
Publication of JP2008519815A publication Critical patent/JP2008519815A/ja
Publication of JP2008519815A5 publication Critical patent/JP2008519815A5/ja
Application granted granted Critical
Publication of JP5274838B2 publication Critical patent/JP5274838B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007540716A 2004-11-12 2005-11-11 化合物 Expired - Fee Related JP5274838B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0425039A GB0425039D0 (en) 2004-11-12 2004-11-12 Chemical compounds
GB0425039.5 2004-11-12
GB0510348.6 2005-05-20
GB0510348A GB0510348D0 (en) 2005-05-20 2005-05-20 Chemical compounds
PCT/GB2005/004361 WO2006051314A2 (en) 2004-11-12 2005-11-11 Guanidine derivatives as inhibitors of ddah

Publications (3)

Publication Number Publication Date
JP2008519815A JP2008519815A (ja) 2008-06-12
JP2008519815A5 true JP2008519815A5 (enExample) 2008-11-20
JP5274838B2 JP5274838B2 (ja) 2013-08-28

Family

ID=35908037

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007540716A Expired - Fee Related JP5274838B2 (ja) 2004-11-12 2005-11-11 化合物

Country Status (6)

Country Link
US (1) US8063104B2 (enExample)
EP (1) EP1828109B1 (enExample)
JP (1) JP5274838B2 (enExample)
AU (1) AU2005303610B2 (enExample)
CA (1) CA2587444C (enExample)
WO (1) WO2006051314A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005303610B2 (en) 2004-11-12 2011-07-21 Ucl Business Plc Guanidine derivatives as inhibitors of DDAH
EP2695608B1 (en) * 2006-10-03 2016-11-23 Arbutus Biopharma Corporation Lipid containing formulations
DE102008061247A1 (de) 2008-12-10 2010-06-24 Christian-Albrechts-Universität Zu Kiel Inhibitoren der Dimethylarginin Dimethylaminohydrolase
US9011882B2 (en) 2012-02-14 2015-04-21 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
WO2014160947A1 (en) * 2013-03-29 2014-10-02 The Board Of Trustees Of The Leland Stanford Junior University Dimethylarginine dimethylaminohydrolase inhibitors and methods of use thereof
US10226418B2 (en) 2014-05-12 2019-03-12 Susie Q, Ltd. Arginine-containing topical composition
AU2018354090B2 (en) 2017-10-23 2024-10-24 Epitracker, Inc. Fatty acid analogs and their use in the treatment of conditions related to metabolic syndrome
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
WO2020146263A1 (en) * 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
US12370166B2 (en) 2021-11-03 2025-07-29 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
WO2023084531A1 (en) 2021-11-12 2023-05-19 Celagenex Research (India) Pvt. Ltd. A synergistic composition for activating intracellular secondary messenger(camp) pathway

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI832053L (fi) 1982-06-10 1983-12-11 Syntex Inc Nonapeptid- och dekapeptidanaloger av lhrh anvaendbara som lhrh-antagonister samt deras framstaellningsfoerfarande
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4659693A (en) * 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
US4686283A (en) * 1985-04-16 1987-08-11 Syntex (U.S.A.) Inc. Analogs of transforming and epidermal growth factor fragments for therapy and diagnosis
IT1201511B (it) * 1985-12-23 1989-02-02 Italfarmaco Spa Derivati citoprotettivi in patologie a base ischemica,loro preparazione e composizioni che li cntengono
US5352796A (en) * 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5318992A (en) * 1990-02-26 1994-06-07 Merrell Dow Pharmaceuticals Inc. Inhibitors of nitric oxide biosynthesis
MX9100717A (es) * 1990-08-24 1992-04-01 Syntex Inc Antagonistas de la bradiquinina
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5859295A (en) * 1994-12-05 1999-01-12 University Of Kentucky Research Foundation Canavanine analogs and their use as chemotherapeutic agents
GB9504350D0 (en) * 1995-03-04 1995-04-26 Sod Conseils Rech Applic Arginine derivatives
EP1038864A1 (en) 1997-12-12 2000-09-27 Fuji Yakuhin Kogyo Kabushiki Kaisha Novel metalloproteinase inhibitors
ATE355308T1 (de) 1998-07-16 2006-03-15 Univation Tech Llc Lewis-säure cokatalysatoren auf aluminium-basis für die olefinpolymerisation
EP1022268A1 (en) 1999-01-02 2000-07-26 Aventis Pharma Deutschland GmbH Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
AU2285700A (en) 1999-01-02 2000-07-24 Aventis Pharma Deutschland Gmbh Arylalkanoyl derivatives, processes for their preparation, their use and pharmaceutical compositions containing them
AU3511500A (en) 1999-03-05 2000-09-21 Trustees Of University Technology Corporation, The Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions
FR2794974B1 (fr) * 1999-06-16 2001-08-17 Exsymol Sa Composition cosmetique pour l'amincissement a base de l-arginine, d'un analogue de l-arginine ou d'un de leurs derives, applicable par voie topique
JP2002241308A (ja) * 2001-02-21 2002-08-28 Ikeda Mohandou:Kk 皮膚そう痒症治療薬
GB0211295D0 (en) 2002-05-16 2002-06-26 Univ London Treatment of pain
AU2005303610B2 (en) 2004-11-12 2011-07-21 Ucl Business Plc Guanidine derivatives as inhibitors of DDAH

Similar Documents

Publication Publication Date Title
JP5576485B2 (ja) 新生物疾患又は自己免疫疾患を処置するためのプロドラッグとしてのフラザノベンゾイミダゾール
JP2014503574A5 (enExample)
JP2018522866A5 (enExample)
EA200970670A1 (ru) Производные 3-амино-пирроло[3,4-c]пиразол-5(1h,4h,6h)-карбальдегида в качестве ингибиторов ркс
RU2009123525A (ru) ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2
JP2008519815A5 (enExample)
JP2015522650A5 (enExample)
JP2009535307A5 (enExample)
JP2014532716A5 (enExample)
JP2018522867A5 (enExample)
JP2007520440A5 (enExample)
JP2012504608A5 (enExample)
JP2016507502A5 (enExample)
JP2018529690A5 (enExample)
CZ113692A3 (en) Quinoxalines, process of their preparation and their use
JP2016540803A5 (enExample)
JP2019513830A (ja) 抗ｂ型肝炎ウイルスのピラゾール−オキサゾリジノン系化合物
JP2017137323A (ja) 新規抗がん剤
EP3472133B1 (en) Perk inhibitors and uses thereof in treating diseases associated with aggregation-prone proteins
JP2007518798A5 (enExample)
AU2011271480B2 (en) Riminophenazines with 2-(heteroaryl)amino substituents and their anti-microbial activity
JP2006500372A5 (enExample)
RU2008112181A (ru) Применение конденсированных производных имидазола для лечения заболеваний, опосредованных рецептором ccr3
JP2014532688A5 (enExample)
JP2013532146A5 (enExample)